Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE enjoys best day since July; mid-caps gain for 4th week

Fri, 22nd Nov 2019 10:09

* FTSE 100 up 1.2%, FTSE 250 up 0.6%

* Indexes bounce back after 2 days of losses

* Pound falls after PMI data, aids exporters

* Mid-cap Hochschild Mining, Coats Group underperform
(Adds news items, updates to closing prices)

By Shashwat Awasthi and Yadarisa Shabong

Nov 22 (Reuters) - London's FTSE 100 surged more than 1% on
Friday after two days of selling, as investors turned cautiously
optimistic about a Sino-U.S. trade deal and exporter stocks rose
after the pound weakened on downbeat U.K. Purchasing Managers'
Indexes (PMI) data.

The main index was powered on its best day since
late July by trade-sensitive scrips including HSBC and
miners and further bolstered by
internationally-exposed firms such as Unilever and
Diageo.

The FTSE 250 added 0.6%, though gains were capped by
data that showed British business this month suffered its
deepest downturn since mid-2016 amid uncertainty around the
general election and Brexit.

Further keeping gains in check was a 9% slide in Hochschild
Mining after its 2020 output targets disappointed, and
an 8% drop in thread manufacturer Coats Group after it
warned on annual profit.

Hochschild shares endured their worst day since Aug. 2017,
while Coats' shares hit their lowest level in two-and-a-half
years.

Despite this, the mid-caps enjoyed their fourth straight
week of gains, buoyed in recent sessions by polls that point to
a likely Conservative Party victory in the Dec. 12 election.

A Conservative victory is seen as more likely to see through
Brexit and it was this view that led the FTSE 250 to a more than
one-year high earlier this week.

The blue-chip bourse recouped all losses from the past two
sessions as mild risk appetite returned after a report http://bit.ly/2O6RSOl
that Washington may delay tariffs on Chinese imports even if a
deal is not signed by a Dec. 15 deadline.

Furthermore, comments by President Xi Jinping that Beijing
wanted to work out an initial trade pact with Washington and a
softer pound helped the FTSE handily outperform the broader
European benchmark.

"Investors are mindful of the trade deal's importance in
supporting hopes of a global economic recovery next year," FXTM
analyst Han Tan said. "A further escalation in trade tensions
would only undermine the world economy's growth momentum while
amplifying chatter about a recession."

Trade tensions had flared earlier this week after President
Donald Trump threatened to raise tariffs on Chinese imports if
no deal was struck, and after the U.S. Senate backed a bill
supporting protesters in Hong Kong, which drew Beijing's ire.

Shares in AstraZeneca advanced as much as 2.8% after
the drugmaker won earlier-than-expected U.S. regulatory approval
for a leukaemia drug.
(Reporting by Yadarisa Shabong and Shashwat Awasthi in
Bengaluru;
Editing by Subhranshu Sahu, Uttaresh.V and Andrew Cawthorne)

More News
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.